|
|
 |
 | ||
|
|
| ||
|
More to Explore |
|
|
|
|
|
|
Noncoding DNA found to be important
Researchers led by Joel Hirschhorn, MD, PhD, have shown through computational analysis that conserved noncoding sequences (CNCs) aren't just filler, but contain functional bits of genetic sequence whose variation may contribute to human disease.
|
|
|
|
|
Anti-cancer technologies licensed to Genentech
Children's Hospital Boston has granted Genentech an exclusive license to anti-cancer technologies developed in the lab of Vascular Biology researcher Michael Klagsbrun, PhD. These technologies, involving a cell receptor called neuropilin, share a similar mechanism of action with the FDA-approved cancer treatment Avastin.
|
|
|
|
|
Endostatin update, November, 2005
The anti-cancer drug endostatin, discovered in the laboratory of Judah Folkman, MD, has traveled a rocky road to clinical development. Very recently, it seemed the end of the road was near, when the sole U.S. manufacturer stopped making endostatin. But recent developments -- in Folkman's lab and in China -- have given new life to the angiogenesis inhibitor.
|
|
|
|
|
|
|
|
|
Go to Children's News Room to find more research advances.
|
|
|
|
|
|
